Treating nicotine dependence by targeting attention-deficit/hyperactivity disorder (ADHD) with OROS methylphenidate: The role of baseline ADHD severity and treatment response

Journal of Clinical Psychiatry

Volumn 74, Issue 10, 2013, Pages 983-990

  Nunes, Edward V ^a,b   Covey, Lirio S ^a,b   Brigham, Gregory ^c,d   Hu, Mei Chen ^a   Levin, Frances R ^a,b   Somoza, Eugene C ^d,e   Winhusen, Theresa M ^d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Maryhaven Inc   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; METHYLPHENIDATE; NICOTINE PATCH; PLACEBO;

ADHD RATING SCALE IV; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BREATH ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSMOTIC RELEASE ORAL SYSTEM; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SELF REPORT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METHYLPHENIDATE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84887119073     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08155     Document Type: Article

References (49)

1. Compton WM, Thomas YF, Stinson F.S., et al Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(5):566-576. (Pubitemid 46718289)
2. Hasin DS, Stinson FS, Ogburn E, et al Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830-842. (Pubitemid 47026379)
3. O'Brien C P. Review: evidence-based treatments of addiction. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3277-3286.
4. Quitkin FM, Rifkin A, Kaplan J., et al Phobic anxiety syndrome complicated by drug dependence and addiction: a treatable form of drug abuse. Arch Gen Psychiatry. 1972;27(2):159-162.
5. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142(11):1259-1264. (Pubitemid 16216560)
6. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005;162(8): 1483-1493. (Pubitemid 41105562)
7. Nunes E.V., Levin FR Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887-1896. (Pubitemid 38509503)
8. Torrens M, Fonseca F, Mateu G., et al Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1-22. (Pubitemid 40354172)
9. Hobbs JD, Kushner MG, Lee S.S., et al Meta-analysis of supplemental treatment for depressive and anxiety disorders in patients being treated for alcohol dependence. Am J Addict. 2011;20(4):319-329.
10. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.
11. Fiore MC, Jaén CR, Baker T.B., et al Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008.
12. Covey LS, Glassman AH, Jiang H, et al A randomized trial of bupropion and/ or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102(8):1292-1302. (Pubitemid 47037935)
13. Croghan IT, Hurt RD, Dakhil S.R., et al Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007;82(2):186-195. (Pubitemid 46198478)
14. Kessler RC, Adler L, Barkley R., et al The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. (Pubitemid 44464584)
15. Kollins SH, McClernon FJ, Fuemmeler BF Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10):1142-1147. (Pubitemid 41396939)
16. Covey LS, Manubay J, Jiang H., et al Smoking cessation and inattention or hyperactivity/impulsivity: a post hoc analysis. Nicotine Tob Res. 2008; 10(12):1717-1725.
17. Humfleet GL, Prochaska JJ, Mengis M, et al Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. Nicotine Tob Res. 2005;7(3):453-460. (Pubitemid 41418718)
18. Pomerleau OF, Downey KK, Stelson F.W., et al Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7(3):373-378. (Pubitemid 26032582)
19. Wilens TE, Adamson J, Monuteaux M.C., et al Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916-921.
20. Conners CK, Levin ED, Sparrow E, et al Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67-73. (Pubitemid 26176204)
21. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002; 5(4):189-202. (Pubitemid 44844205)
22. Winhusen TM, Somoza EC, Brigham G.S., et al Impact of attention-deficit/ hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(12):1680-1688.
23. Nunes E.V., Pavlicova M, Hu M.C., et al Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials. Am J Drug Al cohol Abu se. 2011;37(5):446-452.
24. Klein D.F., Ross DC Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program general effectiveness report. Neuropsychopharmacology. 1993;8(3):241-251. (Pubitemid 23151392)
25. Fournier JC, DeRubeis RJ, Hollon S.D., et al Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
26. Hesse M. Course of self-reported symptoms of attention deficit and hyperactivity in substance abusers during early treatment. Addict Behav. 2010;35(5):504-506.
27. Safren SA, Sprich SE, Cooper-Vince C, et al Life impairments in adults with medication-treated ADHD. J Atten Disord. 2010;13(5):524-531.
28. Adler LA, Cohen J. Diagnosis and evaluation of adults with attention-deficit/ hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201. (Pubitemid 38452762)
29. DuPaul GJ, Power TJ, Anastopoulos A.D., et al ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
30. Croghan IT, Trautman JA, Winhusen T, et al Tobacco dependence counseling in a randomized multisite clinical trial. Contemp Clin Trials. 2012;33(4):576-582.
31. Sobell LC, Sobell MB Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten R, eds. Techniques to Assess Alcohol Consumption. Totowa, NJ: Humana Press; 1992.
32. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C., et al Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health. 1987;77(11): 1435-1438. (Pubitemid 18011591)
33. Hughes JR, Keely J P, Niaura RS, et al Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25. (Pubitemid 36285465)
34. Heatherton TF, Kozlowski LT, Frecker R.C., et al The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
35. McGrath PJ, Nunes EV, Stewart J W, et al Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53(3):232-240.
36. Nunes EV, Quitkin FM, Donovan S.J., et al Imipramine treatment of opiate-dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55(2):153-160. (Pubitemid 28087601)
37. Hien DA, Jiang H, Campbell A.N., et al Do treatment improvements in PTSD severity affect substance use outcomes? a secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. Am J Psychiatry. 2010;167(1):95-101.
38. Volkow ND, Wang GJ, Newcorn J, et al Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64(8): 932-940. (Pubitemid 47230617)
39. Berlin I, Hu MC, Covey L.S., et al Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD. Drug Alcohol Depend. 2012;124(3):268-273.
40. Henningfield JE, Griffiths RR Cigarette smoking and subjective response: effects of d-amphetamine. Clin Pharmacol Ther. 1981;30(4):497-505.
41. Tidey J.W., O'Neill SC, Higgins ST d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology (Berl). 2000;153(1):85-92. (Pubitemid 32127906)
42. Cousins MS, Stamat HM, de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl). 2001; 157(3):243-253. (Pubitemid 32905565)
43. Rush CR, Higgins ST, Vansickel A.R., et al Methylphenidate increases cigarette smoking. Psychopharmacology (Berl). 2005;181(4):781-789. (Pubitemid 41400764)
44. Vansickel AR, Stoops W W, Glaser PE, et al A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology (Berl). 2007;193(3):305-313. (Pubitemid 47063509)
45. Sigmon SC, Tidey J W, Badger GJ, et al Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology (Berl). 2003;167(4):393-402. (Pubitemid 36754241)
46. Covey LS, Hu MC, Winhusen T, et al OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. Drug Alcohol Depend. 2010;110(1-2):156-159.
47. Covey LS, Hu MC, Weissman J, et al Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate. Nicotine Tob Res. 2011;13(10):1003-1008.
48. The Multimodal Treatment Study of Children with ADHD (MTA) Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086.
49. Pocock SJ, Assmann SE, Enos L.E., et al Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917-2930.